论文部分内容阅读
目的:观察小剂量苯那普利和洛沙坦联合治疗非高血压糖尿病肾病的疗效。方法:将126例正常血压的糖尿病肾病患者随机分为联合治疗组(苯那普利5mg/d+洛沙坦50mg/d)、苯那普利组(苯那普利5mg/d)和洛沙坦组(50mg/d),观察期6个月。治疗前后检测血压、血糖(BG)、尿白蛋白排泄率(UAER)、血清肌酐(SCr)、尿素氮(BUN)、糖化血红蛋白(HbA1C)、血钾(SK+)。结果:3组治疗前后血糖、血清钾、肾功能差异无显著性,但治疗后尿白蛋白排泄率均较治疗前明显下降(P<0.01)。各组间比较,联合治疗组尿蛋白排泄率下降更明显(P<0.05),单独治疗组间比较差异无显著性。结论:小剂量苯那普利和洛沙坦联合治疗合并非高血压的糖尿病肾病疗效显著,安全合理。
Objective: To observe the curative effect of low-dose benazepril combined with losartan on non-hypertensive diabetic nephropathy. Methods: A total of 126 patients with diabetic nephropathy with normotensive hypertension were randomly divided into combined treatment group (benazepril 5mg / d + losartan 50mg / d), benazepril group (benazepril 5mg / d) Tan group (50mg / d), observation period of 6 months. Blood pressure, blood glucose (BG), urinary albumin excretion rate (UAER), serum creatinine (SCr), blood urea nitrogen (BUN), HbA1C and SK + were measured before and after treatment. Results: There was no significant difference in blood glucose, serum potassium and renal function before and after treatment in three groups, but the urinary albumin excretion rate decreased significantly after treatment (P <0.01). Compared with each group, the urinary protein excretion rate decreased more significantly in the combined treatment group (P <0.05), but there was no significant difference between the treatment groups. Conclusion: The combination of benazepril and losartan at low dosage has a significant and safe therapeutic effect on non-hypertensive diabetic nephropathy.